AbbVie’s Inc (NYSE:ABBV) Investigational Regimen Of Gelcaprevir Pibrent Asvir (G/P) Has Been Approved For Review By Health Canada

AbbVie’s Inc (NYSE:ABBV) Investigational Regimen Of Gelcaprevir Pibrent Asvir (G/P) Has Been Approved For Review By Health Canada

It was announced today by AbbVie Inc. (NYSE:ABBV) that their New Drug Review, otherwise known as NDA has been approved for priority review by Health Canada. The drug itself, which was approved is the company’s self-developed investigational regimen of Glecaprevir/Pibrent Asvir (G/P). This drug was developed in order to provide a solution or cure for the treatment of major chronic hepatitis C virus (HCV) genotypes. This drug has been manufactured […]

Read More ˃
Investigation Initiated By Levi & Korsinsky Over The Sale Of CoLucid Pharmaceuticals Inc. (NASDAQ:CLCD)

Investigation Initiated By Levi & Korsinsky Over The Sale Of CoLucid Pharmaceuticals Inc. (NASDAQ:CLCD)

It has been officially announced, through a statement issued, that Levi & Korsinsky is launching an investigation over the sale between CoLucid Pharmaceuticals Inc. (NASDAQ:CLCD), which was purchased by Eli Lilly & Co (NYSE:LLY). The reason behind this investigation is due to the uncertainty that this merger was fair to the shareholders of the organization. More details about the merger and the investigation According to the signed merger agreement, CoLucid […]

Read More ˃
Eli Lilly and Co (NYSE:LLY) & Sanofi SA (ADR)(NYSE:SNY) Among Others Accused Of Price Fixing On Insulin

Eli Lilly and Co (NYSE:LLY) & Sanofi SA (ADR)(NYSE:SNY) Among Others Accused Of Price Fixing On Insulin

The prices foe on drugs from pharmaceutical companies seems to be never ending, of late. In a latest move, Eli Lilly and Co (NYSE:LLY), along with Sanofi SA (ADR)(NYSE:SNY) and Novo Nordisk A/S (ADR)(NYSE:NVO) were accused of “conspiring” in hiking the prices of insulin. As a result, a federal lawsuit is filed against the three in federal court in Massachusetts. Companies exploiting opaque drug-pricing system in the US The feud […]

Read More ˃
Novartis (NYSE:NVS) Withdraws Application For Amgen Biosimilar Candidate From EMA

Novartis (NYSE:NVS) Withdraws Application For Amgen Biosimilar Candidate From EMA

In the last summer, Novartis (NYSE:NVS) did not make much ho-hum about the fact that its application for the doppelganger drug of Neulasta (pegfilgrastim) was rejected by the U.S. FDA. However, in a latest bid, the company’s hope from the EU also crashed. In a recent update, the drug approval body of EMA or European Medicine Agency, CHMP (Committee for Medicinal Products for Human Use) told about withdraw of the […]

Read More ˃